Syngene International Ltd
Pharmaceuticals & Biotechnology | Small Cap
Syngene International Ltd demonstrates a mixed financial performance. The company showcases robust solvency, growth, coverage, and profitability, indicating financial stability and efficient management. Its growth is fueled by increasing revenues and operating profits. However, liquidity and efficiency pose challenges. The company's financial ratios also indicate areas needing attention. While the company excels in key areas, addressing these weaknesses could enhance its overall financial health and competitive position in the healthcare services sector. Syngene's high scores in solvency, growth, coverage, and profitability are tempered by lower scores in liquidity, efficiency and some financial metrics, presenting a balanced picture of strength and areas for improvement.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio2.80
- Profitability Ratio10.00
- Efficiency Ratio6.33
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio6.18
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursBearish
- 4 HoursBearish
- 1 DayBearish
- 1 WeekBullish
- 1 MonthBearish
Syngene International Ltd demonstrates a mixed financial performance. The company showcases robust solvency, growth, coverage, and profitability, indicating financial stability and efficient management. Its growth is fueled by increasing revenues and operating profits. However, liquidity and efficiency pose challenges. The company's financial ratios also indicate areas needing attention. While the company excels in key areas, addressing these weaknesses could enhance its overall financial health and competitive position in the healthcare services sector. Syngene's high scores in solvency, growth, coverage, and profitability are tempered by lower scores in liquidity, efficiency and some financial metrics, presenting a balanced picture of strength and areas for improvement.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
58.38
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
56.08
P/B RATIO
3.67
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
4.75
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
-267.02
EV/EBITDA RATIO
19.03
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹440.75 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤29th Apr 26
Audited Standalone Financial Results for the Quarter and Year Ended March 31, 2026
UNDEFINED SENTIMENT
Quarterly Report⬤22nd Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
The company shows strong and consistent growth. High growth rates in revenue, operating profit, EPS, assets, and net income suggest effective management strategies and market positioning. The company's ability to consistently grow its revenue, profit, and assets signals a promising trajectory. These growth metrics are particularly valuable in the dynamic healthcare services sector.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 19.23 | 22.62 | 9.27 | 4.39 | 2.66 |
| Operating Profit Growth Rate | 9.59 | 26.78 | 7.96 | 2.75 | -12.15 |
| Earnings Per Share (EPS) Growth | -2.37 | 17.11 | 9.68 | -2.84 | -36.25 |
| Asset Growth Rate | 13.95 | 4.8 | 5.51 | 10.47 | 3.81 |
| Net Income Growth Rate | -2.22 | 17.17 | 9.91 | -2.75 | -36.09 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed picture. The company's adjusted EPS and cash EPS are modest, reflecting moderate earnings. The book value per share is also relatively low. The company's capital expenditures are high, indicating significant investments. The healthcare industry's financial dynamics may influence these ratios.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 10.42 | 11.72 | 12.96 | 11.77 | 9.33 |
| Cash Earnings Per Share (Cash EPS) | 17.61 | 20.7 | 23.28 | 23.11 | 19.11 |
| Book Value Per Share | 82.24 | 90.22 | 105.92 | 117.56 | 120.07 |
| Dividend Per Share (DPS) | 0.99 | 1.27 | 1.27 | 1.23 | 1.26 |
| Capital Expenditures (CapEx) | 476 | 518 | 489 | 770 | 368 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates strong profitability. High margins and returns on capital, equity, and assets reflect efficient operations and effective management. The company is generating substantial profit from its sales and investments. The company is creating value for its shareholders. These factors enhance the company's attractiveness to investors in the healthcare services sector.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 16.63 | 18.04 | 16.94 | 16.8 | 12.44 |
| Return on Capital Employed (ROCE) | 13 | 15 | 15 | 14 | 10 |
| Return on Equity (ROE) | 12.01 | 12.82 | 11.98 | 10.5 | 6.55 |
| Return on Assets (ROA) | 13.35 | 16.16 | 16.53 | 15.38 | 13.01 |
| Operating Margin | 28.53 | 29.5 | 29.15 | 28.69 | 24.55 |
| Net Margin | 15.21 | 14.53 | 14.62 | 13.62 | 8.48 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company demonstrates mixed efficiency. Strong inventory management and receivables turnover are offset by less efficient use of fixed assets and capital. The company has efficient inventory and sales management which is useful to reduce holding cost. The less efficient asset turnover ratios may indicate underutilization of resources. These factors could impact the company's competitive positioning within the healthcare services sector.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.09 | 1.2 | 1.22 | 1.3 | 1.24 |
| Inventory Turnover Ratio | 18.17 | 10.22 | 10.15 | 15.39 | 22.04 |
| Receivables Turnover Ratio | 5.29 | 6.16 | 7.19 | 7.52 | 7.22 |
| Days Sales in Inventory Ratio | 20.09 | 35.71 | 35.96 | 23.72 | 16.56 |
| Receivable Days | 69 | 59.25 | 50.76 | 48.54 | 50.55 |
| Capital Turnover Ratio | 0.64 | 0.73 | 0.73 | 0.7 | 0.71 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company exhibits strong coverage ratios. The high interest coverage ratio indicates the company's ability to easily meet its interest obligations. The equity dividend coverage ratio indicates the company can comfortably cover its dividend payments. These factors enhance the company's financial stability and appeal to investors in the healthcare services sector.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 21.17 | 14.2 | 14.21 | 13.45 | 9.39 |
| Equity Dividend Coverage Ratio | 10 | 9.09 | 10 | 10 | 6.25 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits a strong financial position with low debt levels and a high proportion of equity. Low debt ratios suggest a conservative approach to financial leverage. The company's limited reliance on debt reduces its financial risk. These factors could be particularly advantageous in the capital-intensive healthcare services sector, where financial stability is highly valued.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.19 | 0.17 | 0.11 | 0.09 | 0.08 |
| Debt to Equity Ratio | 0.23 | 0.2 | 0.12 | 0.1 | 0.09 |
| Equity Ratio | 0.81 | 0.83 | 0.89 | 0.91 | 0.92 |
| Debt To Asset Ratio | 0.14 | 0.13 | 0.08 | 0.07 | 0.06 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is mixed, indicating both strengths and weaknesses in its ability to meet short-term obligations. An adequate quick ratio provides some reassurance, signaling the firm's capacity to cover its immediate liabilities with its most liquid assets. The company's current ratio suggests potential challenges in covering current liabilities. While the cash ratio reflects a moderate ability to meet obligations with available cash, the operating cash flow ratio highlights the company's capacity to generate cash from its operations.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.19 | 1.39 | 1.39 | 1.29 | 1.28 |
| Quick Ratio | 1.07 | 1.17 | 1.22 | 1.19 | 1.2 |
| Cash Ratio | 0.34 | 0.36 | 0.41 | 0.49 | 0.47 |
| Operating Cash Flow Ratio | 0.39 | 0.56 | 0.75 | 0.73 | 0.52 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.64 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 35.27 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 61.14 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 32.77 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 36.27 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.54 | 22.23 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Syngene International Ltd | 7.44 | 56.08 | Overvalued | 918.00 | 7.55 | 317.00 |
| 8 | Emcure Pharmaceuticals Ltd | 7.40 | 36.42 | Neutral | 1865.00 | 38.66 | 941.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 32.39 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Ipca Laboratories Ltd | 6.33 | 35.26 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 11 | Piramal Pharma Ltd | 5.83 | -64.86 | Neutral | 922.00 | 5.27 | -326.00 |
| 12 | Jubilant Pharmova Ltd | 5.71 | 38.62 | Neutral | 1260.00 | 1.25 | 398.00 |
| 13 | Natco Pharma Ltd | 5.69 | 11.22 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 14 | Wockhardt Ltd | 5.07 | 153.40 | Neutral | 652.00 | 19.51 | 199.00 |
| 15 | Pfizer Ltd | 3.45 | 45.16 | Neutral | -82.00 | 157.92 | 300.00 |
The management of Syngene International demonstrates mixed performance. Revenue growth is evident over the years, but profitability has fluctuated. The company maintains a reasonable Return on Equity (ROE) and Return on Capital Employed (ROCE), indicating efficient use of capital. However, there is a decline in promoter holding and recent sales growth is concerning.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | ROCE | 13.76 | Efficient use of capital. |
| CONS | Promoter Holding | Declining | Confidence and alignment are decreasing. |
| Profit Growth | TTM -9% | Profit growth is declining. |
Financial Performance & Growth
Syngene International has demonstrated revenue growth over the past several years, but recent performance indicates a slowdown. While historical sales growth has been robust, current trends raise concerns.
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Sales (₹ Cr) | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | 3,642 |
| Sales Growth (%) | 28.28 | 10.20 | 8.57 | 19.22 | 22.61 | 9.26 | 4.41 |
While the compounded sales growth over 5 years is 13% and 3 years is 12%, the TTM sales growth is only 4%. This deceleration in sales growth, coupled with fluctuations in quarterly sales growth, suggests potential challenges in maintaining consistent revenue expansion.
Capital Efficiency & Returns
Syngene International demonstrates reasonable capital efficiency, as indicated by its Return on Capital Employed (ROCE). These metrics suggest that the company is utilizing its capital effectively to generate returns.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| ROCE % | 14% | 13% | 15% | 15% | 13% |
The ROCE has remained relatively stable, fluctuating between 13% and 15% over the past five years. A stable ROCE indicates consistent performance in generating profits from its capital investments.
Financial Health & Prudence
Syngene International exhibits a generally healthy financial profile with manageable debt levels. The company's debt-to-equity ratio and interest coverage ratio suggest that it is capable of meeting its financial obligations. Borrowings have decreased in recent years.
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Borrowings (₹ Cr) | 787 | 813 | 773 | 893 | 1,022 | 815 | 555 | 578 |
The reduction in borrowings from ₹1,022 Cr in Mar 2022 to ₹578 Cr in Mar 2025 indicates improved debt management. While the levels of debt seem manageable, the company should focus on maintaining a prudent approach to leverage to ensure long-term financial stability.
Shareholding & Ownership Structure
The shareholding pattern of Syngene International reveals a notable shift in promoter holding over the recent years. While institutional interest has increased, the decrease in promoter stake could raise concerns about long-term strategic alignment.
| Shareholder Type | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Promoters (%) | 54.88 | 54.79 | 52.74 |
| FIIs (%) | 23.31 | 20.92 | 19.47 |
| DIIs (%) | 10.71 | 15.80 | 21.50 |
There has been a continuous decrease in promoter holding. The increase in DII holding indicates growing domestic institutional confidence in the company. The decrease in FII holding also indicates a negative sign.
Syngene International faces moderate risks. The decline in promoter holding and recent profit growth raise concerns about alignment and future profitability. Operational efficiency, as indicated by working capital management, presents mixed signals. While the company exhibits strengths in debt management and the increase in DII holding indicates positive sentiments and reduction in FII.
Segment performance volatility
The volatility in Syngene International's quarterly results, specifically in YOY Sales Growth % and YOY Profit Growth %, indicates potential segment performance volatility. Fluctuations in sales and profit growth across different quarters suggest inconsistency in the performance of various business segments or geographical regions.
| Quarter | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| YOY Sales Growth % | -7.79% | -2.28% | -2.10% | 10.57% | 11.03% |
| YOY Profit Growth % | 6% | -45% | -13% | 15% | -3% |
The inconsistency in segment performance contributes to earnings volatility, which may impact investor confidence.
Foreign exchange or interest rate exposure
Syngene International is exposed to both foreign exchange and interest rate risks, which can impact its financial performance. Fluctuations in currency exchange rates and interest rates can affect the company's revenues, expenses, and overall profitability.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Interest Paid Fin | -18 | -34 | -29 | -14 |
Syngene's financial statements reflect interest expenses. Thus, Syngene should actively manage its exposures to mitigate potential adverse effects on its financial results.
Regulatory compliance cost trends
The trend of increasing expenses, including material, employee, and other costs, indicates rising regulatory compliance costs for Syngene International. These costs can arise from stricter environmental regulations, quality control standards, and other industry-specific requirements.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Expenses (₹ Cr) | 1,806 | 2,251 | 2,472 | 2,601 |
| Material Cost % | 28.76% | 26.94% | 26.66% | 25.88% |
| Employee Cost % | 27.77% | 26.54% | 25.67% | 27.01% |
Rising regulatory compliance costs may negatively impact profitability.
Contingent liability evaluation
Contingent liabilities are potential obligations that may arise depending on the outcome of future events. While the provided data does not explicitly list contingent liabilities, it is essential to evaluate their potential impact on Syngene International's financial health. Such liabilities could include pending legal claims, warranty obligations, or environmental remediation costs. These are crucial for assessing the company's overall risk profile and financial stability.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10440.96Bullish
- SMA 20443.34Bearish
- SMA 50449.50Bearish
- EMA 10441.37Bullish
- EMA 20443.41Bearish
- EMA 50446.79Bearish
- DEMA 10439.81Bullish
- DEMA 20439.67Bullish
- DEMA 50443.87Bearish
- TEMA 10440.55Bullish
- TEMA 20438.63Bullish
- TEMA 50442.01Bearish
- MACD-2.72Bullish
- ADX11.35Weak Trend
- IndicatorValueSignal
- RSI43.77Neutral
- CCI-39.47Neutral
- ROC 90.05Bullish
- ROC 14-1.44Bearish
- ROC 25-2.26Bearish
- Stoch K33.12Neutral
- Stoch D27.75Neutral
- IndicatorValueSignal
- BB Upper450.98Neutral
- BB Middle443.35Neutral
- BB Lower435.71Neutral
- ATR3.38Low Volatility
- IndicatorValueSignal
- MFI51.27Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10441.95Bearish
- SMA 20447.41Bearish
- SMA 50446.98Bearish
- EMA 10442.57Bearish
- EMA 20445.27Bearish
- EMA 50448.16Bearish
- DEMA 10439.43Bullish
- DEMA 20441.79Bullish
- DEMA 50445.00Bearish
- TEMA 10439.26Bullish
- TEMA 20439.20Bullish
- TEMA 50443.43Bearish
- MACD-2.91Bearish
- ADX13.59Weak Trend
- IndicatorValueSignal
- RSI41.55Neutral
- CCI-77.08Neutral
- ROC 9-1.38Bearish
- ROC 14-2.19Bearish
- ROC 25-1.22Bearish
- Stoch K19.86Oversold
- Stoch D17.05Oversold
- IndicatorValueSignal
- BB Upper459.74Neutral
- BB Middle447.41Neutral
- BB Lower435.07Neutral
- ATR4.76Low Volatility
- IndicatorValueSignal
- MFI58.93Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10447.12Bearish
- SMA 20449.23Bearish
- SMA 50453.04Bearish
- EMA 10445.03Bearish
- EMA 20447.24Bearish
- EMA 50449.27Bearish
- DEMA 10441.73Bullish
- DEMA 20444.23Bearish
- DEMA 50451.51Bearish
- TEMA 10439.47Bullish
- TEMA 20443.35Bearish
- TEMA 50N/AN/A
- MACD-2.45Bearish
- ADX22.02Weak Trend
- IndicatorValueSignal
- RSI43.74Neutral
- CCI-124.66Oversold
- ROC 9-3.09Bearish
- ROC 14-3.05Bearish
- ROC 251.05Bullish
- Stoch K12.83Oversold
- Stoch D10.47Oversold
- IndicatorValueSignal
- BB Upper461.93Neutral
- BB Middle449.22Neutral
- BB Lower436.52Neutral
- ATR8.49Low Volatility
- IndicatorValueSignal
- MFI48.08Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10448.44Bearish
- SMA 20450.45Bearish
- SMA 50445.70Bearish
- SMA 100442.50Bearish
- SMA 200543.00Bearish
- EMA 10448.60Bearish
- EMA 20449.79Bearish
- EMA 50449.97Bearish
- EMA 100470.84Bearish
- EMA 200524.65Bearish
- DEMA 10447.06Bearish
- DEMA 20449.33Bearish
- DEMA 50441.61Bearish
- DEMA 100416.59Bullish
- DEMA 200428.66Bullish
- TEMA 10447.11Bearish
- TEMA 20445.65Bearish
- TEMA 50459.58Bearish
- TEMA 100425.59Bullish
- TEMA 200399.46Bullish
- MACD-0.70Bearish
- ADX19.27Weak Trend
- IndicatorValueSignal
- RSI45.08Neutral
- CCI-75.03Neutral
- ROC 14-0.38Bearish
- ROC 25-4.95Bearish
- Stoch K44.94Neutral
- Stoch D52.52Neutral
- IndicatorValueSignal
- BB Upper470.65Neutral
- BB Middle450.45Neutral
- BB Lower430.25Neutral
- ATR14.67Low Volatility
- IndicatorValueSignal
- MFI69.89Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20434.66Bullish
- SMA 50560.88Bearish
- EMA 20465.89Bearish
- EMA 50539.90Bearish
- DEMA 20416.90Bullish
- DEMA 50440.27Bullish
- TEMA 20427.11Bullish
- TEMA 50399.71Bullish
- MACD-32.79Bullish
- ADX31.07Strong Trend
- IndicatorValueSignal
- RSI42.18Neutral
- CCI-74.53Neutral
- ROC 1414.72Bullish
- ROC 25-29.90Bearish
- Stoch K46.87Neutral
- Stoch D48.98Neutral
- IndicatorValueSignal
- BB Upper479.07Neutral
- BB Middle434.66Neutral
- BB Lower390.24Neutral
- ATR38.67Low Volatility
- IndicatorValueSignal
- MFI75.31Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6474.37Bearish
- SMA 12562.19Bearish
- SMA 24670.69Bearish
- EMA 6479.21Bearish
- EMA 12541.47Bearish
- EMA 24606.64Bearish
- DEMA 6420.63Bullish
- DEMA 12447.12Bearish
- DEMA 24538.66Bearish
- TEMA 6420.14Bullish
- TEMA 12408.99Bullish
- TEMA 24456.15Bearish
- MACD-20.76Bearish
- ADX19.23Weak Trend
- IndicatorValueSignal
- RSI43.80Neutral
- CCI-159.30Oversold
- ROC 25-35.86Bearish
- ROC 50-26.04Bearish
- Stoch K10.49Oversold
- Stoch D33.71Neutral
- IndicatorValueSignal
- BB Upper929.94Neutral
- BB Middle640.58Neutral
- BB Lower351.22Neutral
- ATR91.39Low Volatility
- IndicatorValueSignal
- MFI46.97Neutral